Expert Commentary

Hysteroscopic tubal occlusion: How new product labeling can be a resource for patient counseling

Hysteroscopically placed tubal implants are a nonsurgical permanent birth control option for some women, but you need to make sure you explain—and your patient understands—all the benefits, risks, and potential complications.

Author and Disclosure Information

 

References

In November 2016, Bayer, the manufacturer of the permanent birth control tubal implant system (Essure), revised the Essure product labeling in accordance with a US Food and Drug Administration (FDA) guidance document.1 The FDA developed its labeling guidance based on its examination of an increasing number of reported adverse events associated with the system’s use (such as persistent pain, perforation of the uterus and/or fallopian tubes, intra-abdominal or pelvic device migration, abnormal or irregular bleeding, and allergy or hypersensitivity reactions) and its evaluation of a trade complaint regarding allegations initially made in a Citizen Petition.

Changes to the new FDA-approved labeling for Essure include:

  • the addition of a boxed warning listing adverse events that have been reported either in clinical studies or through postmarket surveillance (see Box)
  • updated Instructions for Use document for clinicians and Patient Information Booklet, which contain additional information on safety (contraindications, warnings, and precautions), clinical data, and instructions2,3
  • a Patient-Doctor Discussion Checklist (included within the Patient Information Booklet), designed to support appropriate patient counseling, facilitate the patient’s understanding of birth control options, and explain the benefits and risks associated with the device and what to expect during and after the implantation procedure.3

How will these labeling changes impact clinicians and patients? OBG Managementasked Linda Bradley, MD, Professor of Surgery and Vice Chair of Obstetrics and Gynecology at the Women’s Health Institute, Cleveland Clinic, Cleveland, Ohio, to share her expertise with readers.

Boxed warning is now included in Essure product labeling1“WARNING: Some patients implanted with the Essure System for Permanent Birth Control have experienced and/or reported adverse events, including perforation of the uterus and/or fallopian tubes, identification of inserts in the abdominal or pelvic cavity, persistent pain, and suspected allergic or hypersensitivity reactions. If the device needs to be removed to address such an adverse event, a surgical procedure will be required. This information should be shared with patients considering sterilization with the Essure System for Permanent Birth Control during discussion of the e benefits and risks of the device.”
Reference
1. Essure permanent birth control (Bayer) Instructions for use. http://www.hcp.essure-us.com/assets/pdf/Link%20Essure%20IFU.pdf. Accessed January 5, 2017.

Pages

Next Article: